Noam A. VanderWalde, MD

In this review we discuss the rationale and underlying radiobiologic concepts for hypofractionation, and review the clinical trials and ASTRO guidelines supporting hypofractionated radiation in the treatment of breast cancer.

At the ASCO/AACR Joint Session on Inflammatory Cells and Cancer, Dr. Andrew Dannenberg from Weill Cornell Medical College, gave a fascinating lecture titled “Stromal Inflammation and Solid Tumors.”

As a radiation oncologist in training with interests in multiple disease sites, geriatrics, and health services research, I find ASCO extremely educational, motivating, and often frustrating: There is absolutely no way to attend every session of interest.

I would argue that the “personalized” care that geriatric oncologists are championing should be the future of oncology as much as the “precision” care of immune-based and targeted therapies.